These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18680696)

  • 41. The toxicogenetics of antiretroviral therapy: the evil inside.
    Gutierrez Mdel M; Mateo MG; Vidal F; Domingo P
    Curr Med Chem; 2011; 18(2):209-19. PubMed ID: 21110805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
    Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
    Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HLA-B*5701 screening for hypersensitivity to abacavir.
    Faruki H; Lai-Goldman M
    Per Med; 2008 May; 5(3):297-300. PubMed ID: 29783490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.
    Martin AM; Nolan D; Gaudieri S; Phillips E; Mallal S
    Pharmacogenomics; 2004 Sep; 5(6):643-55. PubMed ID: 15335286
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
    Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
    Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
    Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
    Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Will pharmacogenomic discoveries improve HIV therapeutics?
    Haas DW
    Top HIV Med; 2005; 13(3):90-5. PubMed ID: 16170225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
    Vitezica ZG; Milpied B; Lonjou C; Borot N; Ledger TN; Lefebvre A; Hovnanian A
    AIDS; 2008 Feb; 22(4):540-1. PubMed ID: 18301070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.
    Arrieta-Bolaños E; Madrigal JA; Marsh SG; Shaw BE; Salazar-Sánchez L
    Hum Immunol; 2014 Nov; 75(11):1092-6. PubMed ID: 25286002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetics of tenofovir treatment.
    Rodriguez-Novoa S; Labarga P; Soriano V
    Pharmacogenomics; 2009 Oct; 10(10):1675-85. PubMed ID: 19842939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
    Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
    Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV exposure through contact with body fluids.
    Prescrire Int; 2012 Apr; 21(126):100-1, 103-5. PubMed ID: 22515138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring.
    Flexner CW
    Top HIV Med; 2003; 11(2):40-4. PubMed ID: 12717040
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
    AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
    Popoola TD; Awodele O; Oshikoya KA
    Afr J Med Med Sci; 2016 Jun; 45(2):179-187. PubMed ID: 29465861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of IL10, IL4, IFNG, and CTLA4 Gene Polymorphisms with Efavirenz Hypersensitivity Reaction in Patients Infected with Human Immunodeficiency Virus.
    de Oliveira Rodrigues R; Helena Barem Rabenhorst S; Germano de Carvalho P; Luri Sasahara G; Mabel Ferreira Vasconcelos L; Antônio Gomes de Arruda É; Fernandes Ribeiro da Silva S; Farias Ribeiro I; Tiemi Nagao-Dias A
    Jpn J Infect Dis; 2017 Jul; 70(4):430-436. PubMed ID: 28250252
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity.
    Prasertvit P; Chareonyingwattana A; Wattanakrai P
    Contact Dermatitis; 2017 Dec; 77(6):379-384. PubMed ID: 28782122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
    Castillo SA; Hernandez JE; Brothers CH
    Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.